Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Medicine and Dentistry

• Nodular Melanoma 100%
• Mitogen-Activated Protein Kinase 80%
• Combination Therapy 60%
• Neoplasm 40%
• Immunity 40%
• Tumor Cell 40%
• Transcriptomics 40%
• Evolution 40%
• Immunotherapy 20%
• Disease Exacerbation 20%
• Progressive Disease 20%
• Serositis 20%
• Antigen Presentation 20%
• Methylation 20%
• Exhaustion 20%
• Lymphoid Enhancer Factor 1 20%
• Cross Resistance 20%
• Programmed Death-Ligand 1 20%
• Analysis 20%
• Patient 20%
• T Cell 20%
• Cytotoxic T-Cell 20%
• Cell Compartment 20%

INIS

• melanomas 100%
• therapy 60%
• tumors 40%
• tumor cells 40%
• diseases 40%
• dynamics 40%
• immunity 40%
• patients 20%
• compartments 20%
• enrichment 20%
• losses 20%
• mutations 20%
• inflammation 20%
• immunotherapy 20%
• antigens 20%
• methylation 20%

Biochemistry, Genetics and Molecular Biology

• Mitogen-Activated Protein Kinase 80%
• Immunity 40%
• Evolution 40%
• Transcriptomics 40%
• Dynamics 40%
• Mutation 20%
• T Cell 20%
• Methylation 20%
• Antigen Presentation 20%
• CD8 20%
• CpG Site 20%
• Cross Resistance 20%
• Contrast 20%
• Lymphoid Enhancer-Binding Factor 1 20%
• PD-L1 20%
• YAP1 20%
• T Cell Deficiency 20%